Organization | Canadian Immunization Research Network

Canadian Immunization Research Network Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Halifax Canada (2014)

Organization Overview

First Clinical Trial

2014

NCT02712177

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Canadian Immunization Research Network

Active Ingredients

Drugs in Phase 4 Trials (7)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

crm197 (1 trial)

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae b conjugate-hepatitis b vaccine (2 trials)

diphtheria toxoid (1 trial)

menacwy conjugate vaccine (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (3 trials)

tetanus toxoid (1 trial)

Drugs in Phase 2 Trials (4)

azd1222 (1 trial)

bnt162b2 (1 trial)

mrna-1273 (1 trial)

Drugs in Other Trials (2)

4cmenb vaccine (1 trial)

measles, mumps and rubella vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hemorrhagic Fever, Ebola (Phase 2)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Meningococcal Infections (Phase 4)

Pneumococcal Infections (Phase 3)

Pneumonia (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 13